Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut Butzkueven

Showing results (301-310 of 390) with videos related to

Pageof 39
Sort By:
Annals of Clinical and Translational Neurology|May 23, 2015
Predictors of disability worsening in clinically isolated syndromeVilija G Jokubaitis, Tim Spelman, Tomas Kalincik, et al.
Brain, Behavior, and Immunity|December 7, 2025
Biomarkers of neuroaxonal and astrocytic pathology in autoimmune encephalitisRobb Wesselingh, Sarah Griffith, Katherine Ko, et al.
Brain Communications|June 19, 2026
Acute and longitudinal magnetic resonance imaging abnormalities in antibody-mediated encephalitisNabil Seery, Paul Beech, Robb Wesselingh, et al.
Brain : a Journal of Neurology|September 12, 2015
Defining reliable disability outcomes in multiple sclerosisTomas Kalincik, Gary Cutter, Tim Spelman, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 22, 2025
COVID-19 Vaccine Boosters in People With Multiple Sclerosis: Improved SARS-CoV-2 Cross-Variant Antibody Response and Prediction of ProtectionAvani Yeola, Samuel Houston, Anupriya Aggarwal, et al.
Annals of Neurology|April 26, 2017
Prognostic indicators in pediatric clinically isolated syndromePietro Iaffaldano, Marta Simone, Giuseppe Lucisano, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 20, 2025
Managing reactivation of multiple sclerosis during treatment with natalizumabNathaniel Lizak, Sifat Sharmin, Dana Horáková, et al.
JAMA|January 16, 2019
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple SclerosisJ William L Brown, Alasdair Coles, Dana Horakova, et al.
JAMA Neurology|June 12, 2023
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple SclerosisIzanne Roos, Stella Hughes, Gavin McDonnell, et al.
Multiple Sclerosis and Related Disorders|December 27, 2019
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorderAmy Kunchok, Charles Malpas, Petra Nytrova, et al.
Pageof 39

Showing results (301-310 of 390) with videos related to

Sort By:
Pageof 39
Annals of Clinical and Translational Neurology|May 23, 2015
Predictors of disability worsening in clinically isolated syndromeVilija G Jokubaitis, Tim Spelman, Tomas Kalincik, et al.
Brain, Behavior, and Immunity|December 7, 2025
Biomarkers of neuroaxonal and astrocytic pathology in autoimmune encephalitisRobb Wesselingh, Sarah Griffith, Katherine Ko, et al.
Brain Communications|June 19, 2026
Acute and longitudinal magnetic resonance imaging abnormalities in antibody-mediated encephalitisNabil Seery, Paul Beech, Robb Wesselingh, et al.
Brain : a Journal of Neurology|September 12, 2015
Defining reliable disability outcomes in multiple sclerosisTomas Kalincik, Gary Cutter, Tim Spelman, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 22, 2025
COVID-19 Vaccine Boosters in People With Multiple Sclerosis: Improved SARS-CoV-2 Cross-Variant Antibody Response and Prediction of ProtectionAvani Yeola, Samuel Houston, Anupriya Aggarwal, et al.
Annals of Neurology|April 26, 2017
Prognostic indicators in pediatric clinically isolated syndromePietro Iaffaldano, Marta Simone, Giuseppe Lucisano, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 20, 2025
Managing reactivation of multiple sclerosis during treatment with natalizumabNathaniel Lizak, Sifat Sharmin, Dana Horáková, et al.
JAMA|January 16, 2019
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple SclerosisJ William L Brown, Alasdair Coles, Dana Horakova, et al.
JAMA Neurology|June 12, 2023
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple SclerosisIzanne Roos, Stella Hughes, Gavin McDonnell, et al.
Multiple Sclerosis and Related Disorders|December 27, 2019
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorderAmy Kunchok, Charles Malpas, Petra Nytrova, et al.
Pageof 39